AXPAXLI (axitinib intravitreal implant)

Name: AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: Disease description
Published: 2026-09-17T18:54:38-04:00

Neovascular age-related macular degeneration

Also known as OTX-TKI

Manufacturer: Ocular Therapeutix
Regulatory submission: NDA planned for the fourth quarter of 2026
Launch: Anticipated in 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy

Disease description

218 evidence topics · 143 sources

Definition and etiology18 evidence topics · 11 sources
Epidemiology30 evidence topics · 20 sources
Natural history, survival, and mortality12 evidence topics · 12 sources
Pathophysiology12 evidence topics · 7 sources
Diagnosis14 evidence topics · 10 sources
Clinical presentation - signs and symptoms12 evidence topics · 8 sources
Long-term morbidity20 evidence topics · 21 sources
Burden of Neovascular age-related macular degeneration100 evidence topics · 79 sources